A detailed history of Northern Trust Corp transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Northern Trust Corp holds 112,358 shares of BCLI stock, worth $137,076. This represents 0.0% of its overall portfolio holdings.

Number of Shares
112,358
Previous 112,358 -0.0%
Holding current value
$137,076
Previous $38,000 34.21%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.34 - $0.74 $19,573 - $42,601
57,570 Added 105.08%
112,358 $38,000
Q2 2023

Aug 11, 2023

SELL
$2.0 - $3.2 $2,256 - $3,609
-1,128 Reduced 2.02%
54,788 $112,000
Q1 2022

May 13, 2022

SELL
$2.92 - $4.19 $9,271 - $13,303
-3,175 Reduced 5.37%
55,916 $188,000
Q3 2021

Nov 15, 2021

BUY
$3.14 - $4.09 $29,296 - $38,159
9,330 Added 18.75%
59,091 $195,000
Q2 2021

Aug 13, 2021

SELL
$3.01 - $4.01 $751,512 - $1 Million
-249,672 Reduced 83.38%
49,761 $189,000
Q1 2021

May 12, 2021

SELL
$3.46 - $7.88 $17,860 - $40,676
-5,162 Reduced 1.69%
299,433 $1.15 Million
Q4 2020

Feb 11, 2021

SELL
$3.99 - $17.73 $51,574 - $229,177
-12,926 Reduced 4.07%
304,595 $1.38 Million
Q3 2020

Nov 16, 2020

BUY
$11.19 - $16.92 $2.67 Million - $4.03 Million
238,202 Added 300.31%
317,521 $5.37 Million
Q2 2020

Aug 14, 2020

BUY
$4.42 - $12.66 $162,249 - $464,723
36,708 Added 86.15%
79,319 $889,000
Q1 2020

May 14, 2020

BUY
$4.01 - $8.88 $13,914 - $30,813
3,470 Added 8.87%
42,611 $198,000
Q4 2019

Feb 14, 2020

BUY
$3.62 - $4.29 $9,574 - $11,347
2,645 Added 7.25%
39,141 $168,000
Q2 2018

Aug 14, 2018

BUY
$3.12 - $5.19 $7,091 - $11,796
2,273 Added 6.64%
36,496 $142,000
Q3 2017

Nov 13, 2017

BUY
$3.98 - $4.36 $136,207 - $149,212
34,223
34,223 $141,000

Others Institutions Holding BCLI

About BRAINSTORM CELL THERAPEUTICS INC.


  • Ticker BCLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,486,200
  • Market Cap $44.5M
  • Description
  • Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...
More about BCLI
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.